molecules of the month


oral JNK2 kinase inhibitor

Ph. II candidate for pulmonary fibrosis

from HTS and SBDD

Journal of Medicinal Chemistry

Celgene (Bristol Myers Squibb), San Diego, CA

Chemical structure of molecule CC-90001
2 mins read

CC-90001 was nominated by reviewer Christian Kuttruff. CC-90001 is a JNK (c-Jun N-Terminal Kinase) inhibitor and a Phase II clinical candidate for idiopathic pulmonary fibrosis (NCT03142191). Christian says, “Preclinical evidence suggests that c-Jun N-terminal kinase (JNK) enzyme function is required for key steps in the pulmonary fibrotic process. Celgene had previously progressed tanzisertib (CC-930) into Phase 2 clinical trials for IPF but eventually stopped the compound because of the benefit/risk profile.” “With CC-930 displaying a strong JNK2 potency (5 nM over 133 nM for JNK1) and with increasing evidence that JNK1 is the more important isoform to target for fibrotic diseases, the backup program aimed to identify JNK inhibitors with an increased JNK1 bias relative to CC-930. A high throughput…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: